What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2458.png

SCEMBLIX is indicated for the treatment of patients 18 years of age and above with:

 

  • Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). 
  • Previously treated Ph+ CML in CP.
  • Ph+ CML in CP with the T315I mutation.

AE, adverse event; CML, chronic myeloid leukaemia; MOA, mechanism of action; MMR, major molecular remission; Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase; STAMP, Specifically Targeting the ABL1 Myristoyl Pocket; TKI, tyrosine kinase inhibitor; URTI, upper respiratory tract infection.

Frame 427318444.png

A considerable unmet need remains for many CML patients post 2 TKIs

A considerable unmet need remains for many CML patients post 2 TKIs

5

See more details
Hide details
Frame 4273184404.png

MOA: SCEMBLIX is the first and only approved STAMP inhibitor

MOA: SCEMBLIX is the first and only approved STAMP inhibitor

2,4,6,7

See more details
Hide details
Frame 4273180444.png

SCEMBLIX showed superior efficacy vs bosutinib, a 2nd ge TKI, as early as week 24

SCEMBLIX showed superior efficacy vs bosutinib, a 2nd ge TKI, as early as week 24

2

See more details
Hide details
Frame 4273184440.png

SCEMBLIX demonstrated a favourable safety profile vs bosutinib

SCEMBLIX demonstrated a favourable safety profile vs bosutinib

1,2

See more details
Hide details

SCEMBLIX™  20mg and 40mg NSS

PDF
View

References

  1. SCEMBLIX (asciminib) approved Product Information. 

  2. Rea D, Mauro MJ, Boquimpani C, et al. Blood. 2021 Nov 25;138(21):2031-2041. 

  3. Redaelli Set al. J Clin Oncol 2009;27(3):469-71. 

  4. Schoepfer Jet al. J Med Chem 2018;61(18):8120-35. 

  5. Bosi GR,Fogliatto LM, Costa TEV, et al. Hematol Transfus Cell Ther. 2019;41(3):222 228. 

  6. Hughes TP et al. N Engl J Med 2019;38(24):2315–26. 

  7. Manley PW, Barys L, Cowan-Jacob SW. Leuk Res. 2020;98:106458